| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yoshihiro Tadori, Tetsuro Kikuch. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 32. issue 1. 2012-09-13. PMID:22568121. |
aripiprazole is a dopamine d/d3 and serotonin 5-ht1a receptor partial agonist which is approved for treatment of schizophrenia. |
2012-09-13 |
2023-08-12 |
human |
| Yoshihiro Tadori, Tetsuro Kikuch. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 32. issue 1. 2012-09-13. PMID:22568121. |
we evaluated the pharmacological properties of aripiprazole, dopamine d2 receptor partial agonists and antipsychotics using forskolin-stimulated camp accumulation in cells expressing human dopamine d2 and d3 receptors. |
2012-09-13 |
2023-08-12 |
human |
| John M Kane, Raymond Sanchez, Pamela P Perry, Na Jin, Brian R Johnson, Robert A Forbes, Robert D McQuade, William H Carson, W Wolfgang Fleischhacke. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry. vol 73. issue 5. 2012-08-29. PMID:22697189. |
to evaluate the efficacy and tolerability of a once-monthly intramuscular (im) depot formulation of the dopamine partial agonist aripiprazole as maintenance treatment in adults meeting dsm-iv-tr schizophrenia criteria. |
2012-08-29 |
2023-08-12 |
Not clear |
| Beryl Koener, Marylène C Focant, Barbara Bosier, Jean-Marie Maloteaux, Emmanuel Herman. Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry. vol 36. issue 1. 2012-08-20. PMID:21871520. |
substituting nmdg for nacl promoted the response to dopamine and (-)3-ppp and was proven efficient to reveal the partial agonist profile of aripiprazole. |
2012-08-20 |
2023-08-12 |
Not clear |
| Sandra Schönfelder, Frederike Schirmbeck, Robert Waltereit, Susanne Englisch, Mathias Zin. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clinical neuropharmacology. vol 34. issue 6. 2012-08-20. PMID:22104635. |
one suggestive agent for antiobsessive add-on treatment is aripiprazole, a partial agonist at dopamine and serotonin receptors. |
2012-08-20 |
2023-08-12 |
Not clear |
| Jason M Wiebelhaus, Sarah A Vunck, Herbert Y Meltzer, Joseph H Porte. Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice. Behavioural pharmacology. vol 23. issue 3. 2012-08-20. PMID:22547022. |
it was found that the parent drug clozapine fully substituted for ndmc, whereas the typical antipsychotic drug haloperidol (dopamine d2 antagonist) and the atypical antipsychotic drug aripiprazole (d2 partial agonist) did not substitute for ndmc. |
2012-08-20 |
2023-08-12 |
mouse |
| Gabriele Masi, Antonella Gagliano, Rosamaria Siracusano, Stefano Berloffa, Tiziana Calarese, Giovanna Ilardo, Chiara Pfanner, Angela Magazù, Clemente Cedr. Aripiprazole in children with Tourette's disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study. Journal of child and adolescent psychopharmacology. vol 22. issue 2. 2012-08-15. PMID:22375853. |
aripiprazole, a partial dopamine agonist, acts as an antagonist at dopamine d2 receptors in hyperdopaminergic conditions and displays agonist properties under hypodopaminergic conditions. |
2012-08-15 |
2023-08-12 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. vol 62. issue 2. 2012-07-27. PMID:21925189. |
dopamine d2 and serotonin 5-ht1a receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. |
2012-07-27 |
2023-08-12 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. vol 62. issue 2. 2012-07-27. PMID:21925189. |
the antipsychotic agent aripiprazole acts as a partial agonist of dopamine d2 and serotonin 5-ht1a receptors. |
2012-07-27 |
2023-08-12 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. vol 62. issue 2. 2012-07-27. PMID:21925189. |
to address this, we examined the effects of systemic and local administrations of aripiprazole on extracellular levels of dopamine and gaba in medial prefrontal cortex (mpfc), nucleus accumbens (nac), and anterior (avta) and posterior (pvta) ventral tegmental areas. |
2012-07-27 |
2023-08-12 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. vol 62. issue 2. 2012-07-27. PMID:21925189. |
intraperitoneal injection of aripiprazole (0.5mg/kg) increased dopamine release in mpfc without affecting those in avta, pvta, or nac, whereas 10mg/kg decreased the release in all four regions. |
2012-07-27 |
2023-08-12 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. vol 62. issue 2. 2012-07-27. PMID:21925189. |
local sulpiride administration in avta increased concentration-dependently dopamine release in both avta and nac without affecting that in mpfc, whereas local aripiprazole administration in avta concentration-dependently decreased dopamine release in avta and mpfc without affecting that in nac. |
2012-07-27 |
2023-08-12 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. vol 62. issue 2. 2012-07-27. PMID:21925189. |
local administration of aripiprazole in mpfc increased dopamine and decreased gaba releases, whereas local administration of sulpiride had no effect on dopamine or gaba. |
2012-07-27 |
2023-08-12 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. vol 62. issue 2. 2012-07-27. PMID:21925189. |
in mpfc, blockade of 5-ht1a receptor prevented the aripiprazole-induced dopamine elevation and gaba reduction; however, under the activation of gaba(a) receptor, local perfusion with aripiprazole in mpfc decreased gaba release without affecting dopamine release. |
2012-07-27 |
2023-08-12 |
Not clear |
| Rosalie Broekhof, Manon J Gosselink, Hanno Pijl, Erik J Gilta. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. General hospital psychiatry. vol 34. issue 2. 2012-07-09. PMID:21872335. |
the effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. |
2012-07-09 |
2023-08-12 |
Not clear |
| Joshua A Lile, William W Stoops, Paul E A Glaser, Lon R Hays, Craig R Rus. Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. Journal of psychopharmacology (Oxford, England). vol 25. issue 11. 2012-06-27. PMID:20952456. |
aripiprazole is a dopamine d(2) receptor partial agonist undergoing evaluation as a pharmacotherapy for stimulant-use disorders. |
2012-06-27 |
2023-08-12 |
human |
| Itaru Miura, Satoshi Takeuchi, Akihiko Katsumi, Azuma Mori, Keiko Kanno, Qiaohui Yang, Hirobumi Mashiko, Yoshihiko Numata, Shin-Ichi Niw. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. Journal of clinical psychopharmacology. vol 32. issue 1. 2012-05-23. PMID:22198450. |
effects of aripiprazole and the taq1a polymorphism in the dopamine d2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. |
2012-05-23 |
2023-08-12 |
Not clear |
| Richard J Wix-Ramos, Reinalis Paez, Eduardo Capote, Uribe Ezequie. Pituitary microadenoma treated with antipsychotic drug aripiprazole. Recent patents on endocrine, metabolic & immune drug discovery. vol 5. issue 1. 2012-04-06. PMID:22074578. |
we also consider the correlation of drug use in patient with psychosis, haloperidol treatment, pituitary microadenoma syndrome, hyperprolactinemia, and dopamine d2- receptor partial agonist aripiprazole treatment. |
2012-04-06 |
2023-08-12 |
Not clear |
| Takashi Ueda, Shinya Ugawa, Yusuke Ishida, Shoichi Shimad. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. European journal of pharmacology. vol 671. issue 1-3. 2012-03-01. PMID:21951966. |
the developed assay was also able to reproduce the partial agonist activity, the low intrinsic activity and the selective activation of aripiprazole at the dopamine d(2l) receptors. |
2012-03-01 |
2023-08-12 |
Not clear |
| Takashi Ueda, Shinya Ugawa, Yusuke Ishida, Shoichi Shimad. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. European journal of pharmacology. vol 671. issue 1-3. 2012-03-01. PMID:21951966. |
interestingly, gm showed a relatively low intrinsic activity and evoked a partial activation response in a subset of cells expressing the dopamine d(2l) receptor; both of these effects were similarly observed for aripiprazole. |
2012-03-01 |
2023-08-12 |
Not clear |